RT Journal Article
SR Electronic
T1 Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP ERJ-00325-2015
DO 10.1183/13993003.00325-2015
A1 Marie-Josee J. Mangen
A1 Mark H. Rozenbaum
A1 Susanne M. Huijts
A1 Cornelis H. van Werkhoven
A1 Douwe F. Postma
A1 Mark Atwood
A1 Anna M.M. van Deursen
A1 Arie van der Ende
A1 Diederick E. Grobbee
A1 Elisabeth A.M. Sanders
A1 Reiko Sato
A1 Theo J.M. Verheij
A1 Conrad E. Vissink
A1 Marc J.M. Bonten
A1 G. Ardine de Wit
YR 2015
UL http://erj.ersjournals.com/content/early/2015/07/09/13993003.00325-2015.abstract
AB The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13-vaccination in the Netherlands.Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13-vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13-vaccination of adults aged 65–74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted.The ICER for base-case was €8650 per QALY (95% CI 5750–17 100). Vaccination of high-risk individuals aged 65–74 years was cost-saving and extension to medium-risk individuals aged 65–74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13-vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.Vaccinating the elderly with 13-valent pneumococcal conjugate vaccine is highly cost-effective http://ow.ly/NVeui